Clinical trials and socioeconomic implication in the treatment of bone metastasis: A report from the American college of radiology appropriateness criteria expert panel on radiation oncology

Journal of Palliative Medicine

Volumn 12, Issue 5, 2009, Pages 427-431

  Janjan, Nora ^a   Lutz, Stephen T ^b,h   Bedwinek, John M ^c   Hartsell, William F ^d   Pieters, Richard S ^e   Silberstein, Edward B ^f   Yasko, Alan W ^g  

^a UNIVERSITY OF TEXAS   (United States)

^b Blanchard Valley Regional Cancer Center   (United States)

^c Missouri Cancer Care   (United States)

^d Advocate Good Samaritan Hospital   (United States)

^e UMASS MEMORIAL MEDICAL CENTER   (United States)

^f Society of Nuclear Medicine   (United States)

^g MED Orthopedic Surgery   (United States)

^h AMERICAN COLLEGE OF RADIOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; PAMIDRONIC ACID;

ANALGESIA; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER THERAPY; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; EDITORIAL; EXTERNAL BEAM RADIOTHERAPY; HEALTH CARE COST; HUMAN; MULTIMODALITY CANCER THERAPY; ONCOLOGY; PRACTICE GUIDELINE; QUALITY OF LIFE; SOCIOECONOMICS;

BONE NEOPLASMS; CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; DIPHOSPHONATES; EVIDENCE-BASED MEDICINE; HUMANS; PALLIATIVE CARE; PRACTICE GUIDELINES AS TOPIC; UNITED STATES;

EID: 66749164174     PISSN: 10966218     EISSN: None     Source Type: Journal    
DOI: 10.1089/jpm.2009.9632     Document Type: Editorial

References (43)

1. Lubitz JD, Riley GF: Trends in Medicare payments in the last year of life. N Engl J Med 1993;328:1092-1096.
2. American Cancer Society: Cancer Facts and Figures 2005. Atlanta, GA: American Cancer Society 2006., p. 20.
3. Dale RG, Jones B: Radiobiologically based assessments of the net costs of fractionated radiotherapy. Int J Radiat Oncol Biol Phys 1996;36:739-746.
4. Janjan NA: Radiotherapeutic approaches to cancer pain management. Highlights in Oncol Pract 1997;14:103-113.
5. Hillner BE, Weeks JC, Desch CE, Smith TJ: Pamidronate in prevention of bone complications in metastatic breast cancer: A cost-effectiveness analysis. J Clin Oncol 2000;18:72-79.
6. Dranitsaris G, Hsu T: Cost utility analysis of prophylactic pamidronate for the prevention of skeletal related events in patients with advanced breast cancer. Support Care Cancer 1999;7:271-279.
7. Hortobagyi GN, Theriault RL, Lipton A, Porter L, Blayney D, Sinoff C, Wheeler H, Simeone JF, Seaman JJ, Knight RD, Heffernan M, Mellars K, Reitsma DJ: Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol 1998;16:2038-2044.
8. Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C, Wheeler H, Simeone JF, Seaman J, Knight RD: Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med 1996;335:1785-1791.
9. Lipton A, Theriault RL, Hortobagyi GN, Simeone J, Knight RD, Mellars K, Reitsma DJ, Heffernan M, Seaman JJ: Pamidronate prevents skeletal complications and is effective palliative treatment in women withbreast carcinoma and osteolyticbone metastases: Long term follow-up of two randomized, placebo-controlled trials. Cancer 2000;88:1082-1090.
10. Gainford MC, Dranitsaris G, demons M: Recent developments in bisphosphonates for patients with metastatic breast cancer. BMJ 2005;330:769-773.
11. Hartsell WF, Scott CB, Bruner DW, Scarantino CW, Ivker RA, Roach M 3rd, Suh JH, Demas WF, Movsas B, Petersen IA, Konski AA, Cleeland CS, Janjan NA, DeSilvio M: Randomized trial of short-versus long-course radiotherapy for palliation of painful bone metastases. J Natl Cancer Inst 2005;97:798-804.
12. Centers for Medicare and Medicaid Services, Office of the Actuary. www.cms.hhs.gov/NationalHealthExpendData/ (Last accessed March 11, 2009). Swq12
13. Kaiser Family Foundation/Harvard School of Public Health: Health Care Costs Survey. USA Today August 2005.
14. Appleby J: More insured workers unable to pay medical bills. USA Today April 2005.
15. Arozullah AM, Calhoun EA, Wolf M, Wolf M, Finley DK, Fitzner KA, Heckinger EA, Gorby NS, Schumock GT, Bennett CL: The financial burden of cancer: estimates from a study of insured women with breast cancer. J Support Oncol 2004;2:271-278.
16. Emanuel EJ: Cost savings at the end of life. What do the data show? JAMA 1996;275:1907-1914.
17. Emanuel EJ, Ash A, Yu W, Gazelle G, Levinsky NG, Saynina O, McClellan M, Moskowitz M: Managed care, hospice use, site of death, and medical expenditures in the last year of life. Arch Intern Med 2002;162:1722-1728.
18. Gabel J, Claxton G, Gil I, Pickreign J, Whitmore H, Finder B, Hawkins S, Rowland D: Health benefits in 2005: Premium increases slow down, coverage continues to erode. Health Aff (Millwood) 2005;24:1273-1280.
19. Haupt BJ: Characteristics of hospice care discharges and their length of service: United States, 2000. Vital Health Stat 13, 2003;13:1-36.
20. Mertens WC, Hoople NE, Rodrigues C, Lindenauer PK, Benjamin EM: Association of admission date with cancer patient survival at a regional hospice: Utility of a statistical process control analysis. Am J Hosp Palliat Care 2004;21:275-284.
21. Slutsman J, Emanuel LL, Fairclough D, Bottorff D, Emanuel EJ: Managing end-of-life care: Comparing the experiences of terminally 111 patients in managed care and fee for service. J Am Geriatr Soc 2002;50:2077-2083.
22. Smith C, Cowan C, Sensenig A, Catlin A: Health spending growth slows in 2003. Health Aff (Millwood) 2005;24:185-194.
23. National Health Care Expenditures 1960-2005. Centers for Medicare and Medicaid Services, Office of the Actuary: Data from the National health Statistics Group, www.cms.hhs.gov/NationalHealthExpendData/02- NationalHealthAccounts Historical.asp#TopOfPage (Last accessed March 11, 2009).
24. A controlled trial to improve care for seriously ill hospitalized patients. The study to understand prognoses and preferences for outcomes and risks of treatments (SUPPORT). The SUPPORT Principal Investigators. JAMA 1995;274:1591-1598.
25. Field MJ, Cassel CK (eds): Approaching Death: Improving Care at the End of Life. Washington D.C.: National Academy Press; 1997.
26. Covinsky KE, Fuller JD, Yaffe K, Johnston CB, Hamel MB, Lynn J, Teno JM, Phillips RS. Communication and decision-making in seriously ill patients: findings of the SUPPORT project. The Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments. J Am Geriatr Soc 2000;48(5 Suppl):S187-193.
27. Gamble ER, McDonald PJ, Lichstein PR: Knowledge, attitudes, and behavior of elderly persons regarding living wills. Arch Intern Med 1991;151:277-280.
28. Garas N, Pantilat SZ: Chapter 49. Advance Planning For End-of-Life Care. AHRQ Evidence Reports, Numbers 1-60. Washington, D.C.: Agency for Healthcare Research and Quality. www.ahrq.gov/clinic/ptsafety/chap49.htm (Last accessed March 11, 2009).
29. Teno J, Lynn J, Wenger N, Phillips RS, Murphy DP, Connors AF Jr, Desbiens N, Fulkerson W, Bellamy P, Knaus WA: Advance directives for seriously ill hospitalized patients: Effectiveness with the patient self-determination act and the SUPPORT intervention. SUPPORT Investigators. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatment. J Am Geriatr Soc 1997;45:500-507.
30. Teno JM, Licks S, Lynn J, Connors AF Jr, Phillips RS, O'Connor MA, Murphy DP, Fulkerson WJ, Desbiens N, Knaus WA: Do advance directives provide instructions that direct care? SUPPORT Investigators. Study to Understand
31. Prognoses and Preferences for Outcomes and Risks of Treatment. J Am Geriatr Soc 1997;45:508-512.
32. Wenger NS, Phillips RS, Teno JM, Oye RK, Dawson NV, Liu H, Califf R, Layde P, Hakim R, Lynn J: Physician understanding of patient resuscitation preferences: Insights and clinical implications. J Am Geriatr Soc 2000;48(5 Suppl): S44-51.
33. Emanuel EJ, Fairclough DL, Slutsman J, Emanuel LL: Understanding economic and other burdens of terminal illness: The experience of patients and their caregivers. Ann Intern Med 2000;132:451-459.
34. Plunkett TA, Smith P, Rubens RD: Risk of complications from bone metastases in breast cancer. Implications for management. Eur J Cancer 2000;36:476-482.
35. Sherry MM, Greco FA, Johnson DH, Hainsworth JD: Breast cancer with skeletal metastases at initial diagnosis. Distinctive clinical characteristics and favorable prognosis. Cancer 1986;58:178-182.
36. Sherry MM, Greco FA, Johnson DH, Hainsworth JD: Meta-static breast cancer confined to the skeletal system. An indolent disease. Am J Med 1986;81:381-386.
37. Sabbatini P, Larson SM, Kremer A, Zhang ZF, Sun M, Yeung H, Imbriaco M, Horak I, Conolly M, Ding C, Ouyang P, Kelly WK, Scher HI: Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. J Clin Oncol 1999;17:948-957.
38. Riley GF, Lubitz JD: Longitudinal patterns of Medicare use by cause of death. Health Care Financ Rev 1989;11:1-12.
39. Riley GF, Potosky AL, Lubitz JD, Kessler LG: Medicare payments from diagnosis to death for elderly cancer patients by stage at diagnosis. Med Care 1995;33:828-841.
40. Emanuel EJ, Young-Xu Y, Levinsky NG, Gazelle G, Saynina O, Ash AS: Chemotherapy use among Medicare beneficiaries at the end of life. Ann Intern Med 2003;138:639-643.
41. Earle CC, Neville BA, Landrum MB, Ayanian JZ, Block SD, Weeks JC: Trends in the aggressiveness of cancer care near the end of life. J Clin Oncol 2004;22:315-321.
42. Earle CC, Neville BA, Landrum MB, Souza JM, Weeks JC, Block SD, Grunfeld E, Ayanian J: Evaluating claims-based indicators of the intensity of end-of-life cancer care. Int J Qual Health Care 2005;17:505-509.
43. Porzsolt F: Goals of palliative cancer therapy: Scope of the problem. Cancer Treat Rev 1993;19(Suppl A):3-14.